Sentinel lymph node detection using 99mTc combined with methylene blue cervical injection for endometrial cancer surgical management: a prospective study

What Was Tested

This observational study looks at Methylene blue (non-peptide stack partner) in the context of endometriosis.

Who Took Part

The abstract describes 2013 women taking part.

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, women only.

This is a single-center prospective observational study carried out from September 2011 to December 2013 including women with a diagnosis of endometrial cancer and scheduled for surgery.

How the Study Was Run

A regional lymph node mapping was obtained using SPECT-CT (cervical injection of Tc) the day before surgery.

On the day of surgery, methylene blue was injected in the cervical tissue.

The SLNs were identified intraoperatively guided both by a γ-probe and visual inspection of the blue dye.

A pelvic and/or para-aortic lymphadenectomy was completed.

A histological analysis was performed on all the removed lymph nodes.

What Was Measured

The subject headings attached to it are Adenocarcinoma, Clear Cell, Carcinoma, Papillary, Cystadenocarcinoma, Serous, Disease Management, Endometrial Neoplasms, Injections, Epidural and Methylene Blue.

What This Means in Plain Language

This is an observational study of Methylene blue (non-peptide stack partner) in 2013 women in people with endometriosis.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, Endometriosis research.